Literature DB >> 21978091

Combination of transcranial sonography, olfactory testing, and MIBG myocardial scintigraphy as a diagnostic indicator for Parkinson's disease.

M O Izawa1, H Miwa, Y Kajimoto, T Kondo.   

Abstract

BACKGROUND: Appropriate diagnostic biomarkers are useful for improving speed and accuracy of a diagnosis. Substantia nigra (SN) hyperechogenicity visualized by transcranial sonography (TCS), olfactory dysfunction, and the reduced uptake of (123) I-metaiodobenzylguanidine (MIBG) in myocardial scintigraphy have been suggested as potential biomarkers for the identification of Parkinson's disease (PD).
OBJECTIVES: To evaluate the diagnostic potential of these tests and to determine whether combining them increases their diagnostic power.
METHODS: Subjects were 44 patients with clinically diagnosed PD and 36 healthy controls. TCS of the SN, the odor stick identification test for Japanese (OSIT-J), and MIBG myocardial scintigraphy were conducted.
RESULTS: Eleven patients with PD (25%) and four controls (11%) were excluded because of an insufficient acoustic temporal bone window in the TCS. Thus, 33 patients with PD and 32 healthy controls were finally included. The diagnostic sensitivity of TCS, OSIT-J, and MIBG myocardial scintigraphy was 78.8%, 84.8%, and 60.6%, respectively. The specificity of TCS and OSIT-J was 93.8% and 78.1%, respectively. The combination of TCS of the SN and OSIT-J substantially increased the sensitivity to a sufficient level for discriminating patients with PD from controls.
CONCLUSION: TCS of the SN and olfactory testing play complementary roles in increasing diagnostic power in PD. As both tests are easy to perform, noninvasive, and inexpensive, the combination of TCS of the SN and olfactory testing may contribute to early and accurate diagnosis of PD.
© 2011 The Author(s). European Journal of Neurology © 2011 EFNS.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21978091     DOI: 10.1111/j.1468-1331.2011.03533.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  13 in total

1.  Comparison of I-123 MIBG planar imaging and SPECT for the detection of decreased heart uptake in Parkinson disease.

Authors:  Jin-Kyoung Oh; Eun-Kyoung Choi; In-Uk Song; Joong-Seok Kim; Yong-An Chung
Journal:  J Neural Transm (Vienna)       Date:  2015-05-24       Impact factor: 3.575

Review 2.  Developments in the role of transcranial sonography for the differential diagnosis of parkinsonism.

Authors:  Andrea Pilotto; Rezzak Yilmaz; Daniela Berg
Journal:  Curr Neurol Neurosci Rep       Date:  2015-07       Impact factor: 5.081

3.  Predictors of postprandial hypotension in elderly patients with de novo Parkinson's disease.

Authors:  Tadashi Umehara; Atsuo Nakahara; Hiromasa Matsuno; Chizuko Toyoda; Hisayoshi Oka
Journal:  J Neural Transm (Vienna)       Date:  2016-07-08       Impact factor: 3.575

Review 4.  Recent developments in biomarkers in Parkinson disease.

Authors:  Anthony H V Schapira
Journal:  Curr Opin Neurol       Date:  2013-08       Impact factor: 5.710

5.  The diagnostic accuracy of dopamine transporter SPECT imaging to detect nigrostriatal cell loss in patients with Parkinson's disease or clinically uncertain parkinsonism: a systematic review.

Authors:  Sven R Suwijn; Caroline Jm van Boheemen; Rob J de Haan; Gerrit Tissingh; Jan Booij; Rob Ma de Bie
Journal:  EJNMMI Res       Date:  2015-03-17       Impact factor: 3.138

Review 6.  Diagnostic Accuracy of Transcranial Sonography of the Substantia Nigra in Parkinson's disease: A Systematic Review and Meta-analysis.

Authors:  Dun-Hui Li; Ya-Chao He; Jun Liu; Sheng-Di Chen
Journal:  Sci Rep       Date:  2016-02-16       Impact factor: 4.379

7.  Usefulness of Cardiac MIBG Scintigraphy, Olfactory Testing and Substantia Nigra Hyperechogenicity as Additional Diagnostic Markers for Distinguishing between Parkinson's Disease and Atypical Parkinsonian Syndromes.

Authors:  Hiroaki Fujita; Keisuke Suzuki; Ayaka Numao; Yuji Watanabe; Tomoyuki Uchiyama; Tomoyuki Miyamoto; Masayuki Miyamoto; Koichi Hirata
Journal:  PLoS One       Date:  2016-11-03       Impact factor: 3.240

8.  Diagnostic Value of Combined Acute Levodopa Challenge and Olfactory Testing to Predict Parkinson's Disease.

Authors:  Cinthia Terroba Chambi; Malco Rossi; Andrea Bril; Patricio Millar Vernetti; Daniel Cerquetti; Angel Cammarota; Marcelo Merello
Journal:  Mov Disord Clin Pract       Date:  2017-09-03

9.  A Brief Nonmotor Screen Combined with Transcranial Ultrasound may Improve Diagnostic Accuracy of Parkinson's Disease.

Authors:  Michael Hayes; Peter Puhl; Johann Hagenah; Robert Russo
Journal:  Mov Disord Clin Pract       Date:  2016-11-01

10.  Combination of olfactory test and substantia nigra transcranial sonopraphy in the differential diagnosis of Parkinson's disease: a pilot study from China.

Authors:  Wei Chen; Yu-Yan Tan; Yun-Yun Hu; Wei-Wei Zhan; Li Wu; Yue Lou; Xi Wang; Yi Zhou; Pei Huang; Yuan Gao; Qin Xiao; Sheng-Di Chen
Journal:  Transl Neurodegener       Date:  2012-12-26       Impact factor: 8.014

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.